Study Confirms
UPMC, 11/05/2013
A new study published online in the American Journal of Obstetrics and Gynecology by researchers from the University of Pittsburgh School of Medicine and the University of Pittsburgh School of Pharmacy reports that 17–hydroxyprogesterone caproate (17–OHPC), a medication that reduces the rate of preterm birth in high–risk women, did not raise any safety concerns when the medication was prepared and dispensed by independent compounding pharmacies throughout the United States. “Contrary to the report provided by the company that markets Makena, we found that 17–OHPC from compounding pharmacies raised no safety concerns about drug potency, sterility or purity,” said Steve N. Caritis, M.D., professor of obstetrics and gynecology at Pitt, and the study’s corresponding author. Dr. Caritis cautioned, however, that the sample size was small and the findings cannot be applied to all compounded products or pharmacies.
No comments:
Post a Comment